SCHEDULE: Contrarius Investment Management Reports 0.6% Stake in Intellia

Contrarius Investment Management entities have reported a 0.6% beneficial ownership stake in Intellia Therapeutics, Inc. as of December 31, 2025.

Summary

• Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited, acting as a group, beneficially own 714,480 shares of Intellia Therapeutics, Inc. common stock.
• This aggregate amount represents 0.6% of Intellia Therapeutics, Inc.'s outstanding common stock.
• The reporting persons hold shared voting power and shared dispositive power over all 714,480 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing or a change in ownership requiring an update.
• The reporting entities are organized under the laws of Jersey, Channel Islands, and Bermuda, respectively, and are classified as financial institutions (investment advisers).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. A 0.6% stake is a relatively small position for an institutional investor and does not indicate a strong bullish or bearish sentiment towards Intellia Therapeutics, Inc.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Contrarius Investment Management certified that the securities were acquired and are held in the ordinary course of business.
• The securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of Intellia Therapeutics, Inc.
• The foreign regulatory scheme applicable to Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited is substantially comparable to the regulatory scheme applicable to functionally equivalent U.S. institutions.

Industry Context

StockSavvy.ai notes that institutional ownership, even at a small percentage like 0.6%, can signal an investment firm's interest in the biotechnology sector, specifically in companies like Intellia Therapeutics that are involved in gene editing technologies such as CRISPR. While this stake is minor, it reflects ongoing institutional portfolio adjustments within the high-growth, high-risk biotech space.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The filing indicates a minor institutional investor's continued or initiated interest, which might be seen as a neutral to slightly positive signal of confidence, though the stake is too small to be highly influential.
• Employees, Customers, Suppliers, Creditors: No direct impact is expected from this beneficial ownership report.

Key Dates

Recommendation

The filing reports a very small beneficial ownership stake (0.6%) by an institutional investor. This level of ownership is not significant enough to warrant a strong buy or sell recommendation based solely on this information. It represents a minor portfolio allocation rather than a high-conviction position, suggesting a 'hold' stance as it provides no new material information about the company's operational or financial performance.

Keywords

Intellia Therapeutics, Contrarius Investment Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, CRISPR